Despite remarkable progress towards personalized human genome sequencing, much about the human genome remains unknown. Only 2% of the human genome codes for protein, yet many studies suggest that the remaining 98% may have non-coding functions and may be related to disease. Recently, tremendous advances in DNA sequencing throughput, speed, and cost have been made by next-generation sequencing, allowing the development of new genomic technologies for powerful ultra-high-throughput, genome-wide annotation of genomic elements. Towards this aim, the Fullwood lab focuses on human genome annotation, transcriptome characterization, and understanding transcription regulation, to promote human personal genomics. One of the uses of personal genomics is in better understanding cancer, which may lead to the development of better therapies with reduced side effects and novel biomarkers. Towards this end, we are focusing on genomic annotation of gastric and other cancer cell lines.